Low-density Lipoprotein Cholesterol Reduction With State-of-the-art Therapy in Secondary Prevention and Major Cardiovascular Adverse Events: Republic of Srpska Registry
Trial Snapshot
- Phase
- Not Applicable
- Sponsor
- Enrollment
- 500
- Locations
- 1
- Primary Endpoint
- Major Cardiovascular Adverse Events
Study Overview
Brief Summary
Recent trials have demonstrated that a reduction in low-density lipoprotein cholesterol (LDL-C) reduces cardiovascular adverse events following acute coronary syndrome (ACS). However, the data coming from the real-world setting are limited. Therefore, the aim of the study is to assess the association between LDL-C changes with prognosis in patients who survive ACS.
Patients with ACS will be followed for mortality and major events for at least 1 year. Changes in LDL-C between the ACS and a 6- to 10-week follow-up visit will be analysed. The associations between quartiles of LDL-C change and therapy intensity with outcomes will be investigated using adjusted Cox regression analyses.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •acute coronary syndrome
Exclusion Criteria
- Not provided
Arms & Interventions
High-intensity statin
Intervention: Statin (Drug)
High-intensity statin plus ezetimib
Intervention: Statin (Drug)
High-intensity statin plus ezetimib plus PCSK9 inhibitor
Intervention: Statin (Drug)
Outcomes
Primary Outcomes
Major Cardiovascular Adverse Events
Time Frame: 1 year
All-cause death, Acute Coronary Syndrom, Need for Myocardial Revascularization
Secondary Outcomes
- LDL reduction(1 year)
Investigators
Bojan Stanetic
Assistant Prof. Bojan Stanetic, MD, PhD
University Clinical Centre of Republic of Srpska